Five Prime Therapeutics Competitors

Five Prime Therapeutics (NASDAQ:FPRX) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, dividends, valuation, earnings and profitability.

Profitability

This table compares Five Prime Therapeutics and Ultragenyx Pharmaceutical's net margins, return on equity and return on assets.

Insider and Institutional Ownership

67.3% of Five Prime Therapeutics shares are owned by institutional investors. 6.4% of Five Prime Therapeutics shares are owned by insiders. Comparatively, 8.2% of Ultragenyx Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Five Prime Therapeutics and Ultragenyx Pharmaceutical's revenue, earnings per share (EPS) and valuation.

Five Prime Therapeutics has higher earnings, but lower revenue than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than Five Prime Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Five Prime Therapeutics has a beta of 4.4, indicating that its share price is 340% more volatile than the S&P 500. Comparatively, Ultragenyx Pharmaceutical has a beta of 2.19, indicating that its share price is 119% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and price targets for Five Prime Therapeutics and Ultragenyx Pharmaceutical, as provided by MarketBeat.

Five Prime Therapeutics presently has a consensus target price of $30.7143, suggesting a potential downside of 19.05%. Ultragenyx Pharmaceutical has a consensus target price of $131.20, suggesting a potential upside of 26.79%. Given Ultragenyx Pharmaceutical's stronger consensus rating and higher probable upside, analysts clearly believe Ultragenyx Pharmaceutical is more favorable than Five Prime Therapeutics.

Summary

Ultragenyx Pharmaceutical beats Five Prime Therapeutics on 8 of the 14 factors compared between the two stocks.

Five Prime Therapeutics (NASDAQ:FPRX) and GW Pharmaceuticals (NASDAQ:GWPH) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, profitability, dividends and earnings.

Profitability

This table compares Five Prime Therapeutics and GW Pharmaceuticals' net margins, return on equity and return on assets.

Institutional and Insider Ownership

67.3% of Five Prime Therapeutics shares are held by institutional investors. Comparatively, 81.0% of GW Pharmaceuticals shares are held by institutional investors. 6.4% of Five Prime Therapeutics shares are held by insiders. Comparatively, 3.1% of GW Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Five Prime Therapeutics and GW Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

GW Pharmaceuticals has higher revenue and earnings than Five Prime Therapeutics. GW Pharmaceuticals is trading at a lower price-to-earnings ratio than Five Prime Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Five Prime Therapeutics has a beta of 4.4, indicating that its stock price is 340% more volatile than the S&P 500. Comparatively, GW Pharmaceuticals has a beta of 2.15, indicating that its stock price is 115% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Five Prime Therapeutics and GW Pharmaceuticals, as provided by MarketBeat.com.

Five Prime Therapeutics presently has a consensus target price of $30.7143, suggesting a potential downside of 19.05%. GW Pharmaceuticals has a consensus target price of $204.0909, suggesting a potential downside of 6.35%. Given GW Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe GW Pharmaceuticals is more favorable than Five Prime Therapeutics.

Summary

GW Pharmaceuticals beats Five Prime Therapeutics on 10 of the 14 factors compared between the two stocks.

Five Prime Therapeutics (NASDAQ:FPRX) and Ascendis Pharma A/S (NASDAQ:ASND) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, profitability, dividends and earnings.

Profitability

This table compares Five Prime Therapeutics and Ascendis Pharma A/S's net margins, return on equity and return on assets.

Institutional and Insider Ownership

67.3% of Five Prime Therapeutics shares are held by institutional investors. 6.4% of Five Prime Therapeutics shares are held by insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Five Prime Therapeutics and Ascendis Pharma A/S's top-line revenue, earnings per share (EPS) and valuation.

Five Prime Therapeutics has higher earnings, but lower revenue than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Five Prime Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Five Prime Therapeutics has a beta of 4.4, indicating that its stock price is 340% more volatile than the S&P 500. Comparatively, Ascendis Pharma A/S has a beta of 0.77, indicating that its stock price is 23% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Five Prime Therapeutics and Ascendis Pharma A/S, as provided by MarketBeat.com.

Five Prime Therapeutics presently has a consensus target price of $30.7143, suggesting a potential downside of 19.05%. Ascendis Pharma A/S has a consensus target price of $187.6667, suggesting a potential upside of 49.40%. Given Ascendis Pharma A/S's stronger consensus rating and higher probable upside, analysts plainly believe Ascendis Pharma A/S is more favorable than Five Prime Therapeutics.

Five Prime Therapeutics (NASDAQ:FPRX) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, profitability, dividends and earnings.

Institutional and Insider Ownership

67.3% of Five Prime Therapeutics shares are held by institutional investors. Comparatively, 65.5% of Arrowhead Pharmaceuticals shares are held by institutional investors. 6.4% of Five Prime Therapeutics shares are held by insiders. Comparatively, 4.0% of Arrowhead Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Five Prime Therapeutics and Arrowhead Pharmaceuticals, as provided by MarketBeat.com.

Five Prime Therapeutics presently has a consensus target price of $30.7143, suggesting a potential downside of 19.05%. Arrowhead Pharmaceuticals has a consensus target price of $85.3077, suggesting a potential upside of 37.26%. Given Arrowhead Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Arrowhead Pharmaceuticals is more favorable than Five Prime Therapeutics.

Volatility and Risk

Five Prime Therapeutics has a beta of 4.4, indicating that its stock price is 340% more volatile than the S&P 500. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.62, indicating that its stock price is 62% more volatile than the S&P 500.

Profitability

This table compares Five Prime Therapeutics and Arrowhead Pharmaceuticals' net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Five Prime Therapeutics and Arrowhead Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Arrowhead Pharmaceuticals has higher revenue and earnings than Five Prime Therapeutics. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Five Prime Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Arrowhead Pharmaceuticals beats Five Prime Therapeutics on 9 of the 14 factors compared between the two stocks.

TG Therapeutics (NASDAQ:TGTX) and Five Prime Therapeutics (NASDAQ:FPRX) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, profitability, earnings, dividends, analyst recommendations and valuation.

Insider & Institutional Ownership

65.7% of TG Therapeutics shares are held by institutional investors. Comparatively, 67.3% of Five Prime Therapeutics shares are held by institutional investors. 13.2% of TG Therapeutics shares are held by company insiders. Comparatively, 6.4% of Five Prime Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings for TG Therapeutics and Five Prime Therapeutics, as reported by MarketBeat.

TG Therapeutics currently has a consensus price target of $64.00, suggesting a potential upside of 42.89%. Five Prime Therapeutics has a consensus price target of $30.7143, suggesting a potential downside of 19.05%. Given TG Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe TG Therapeutics is more favorable than Five Prime Therapeutics.

Risk and Volatility

TG Therapeutics has a beta of 2.28, suggesting that its stock price is 128% more volatile than the S&P 500. Comparatively, Five Prime Therapeutics has a beta of 4.4, suggesting that its stock price is 340% more volatile than the S&P 500.

Profitability

This table compares TG Therapeutics and Five Prime Therapeutics' net margins, return on equity and return on assets.

Valuation & Earnings

This table compares TG Therapeutics and Five Prime Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Five Prime Therapeutics has higher revenue and earnings than TG Therapeutics. TG Therapeutics is trading at a lower price-to-earnings ratio than Five Prime Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Five Prime Therapeutics beats TG Therapeutics on 8 of the 14 factors compared between the two stocks.

Ionis Pharmaceuticals (NASDAQ:IONS) and Five Prime Therapeutics (NASDAQ:FPRX) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, profitability, earnings, dividends, analyst recommendations and valuation.

Insider & Institutional Ownership

84.1% of Ionis Pharmaceuticals shares are held by institutional investors. Comparatively, 67.3% of Five Prime Therapeutics shares are held by institutional investors. 2.4% of Ionis Pharmaceuticals shares are held by company insiders. Comparatively, 6.4% of Five Prime Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings for Ionis Pharmaceuticals and Five Prime Therapeutics, as reported by MarketBeat.

Ionis Pharmaceuticals currently has a consensus price target of $57.9091, suggesting a potential upside of 36.71%. Five Prime Therapeutics has a consensus price target of $30.7143, suggesting a potential downside of 19.05%. Given Ionis Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Ionis Pharmaceuticals is more favorable than Five Prime Therapeutics.

Risk and Volatility

Ionis Pharmaceuticals has a beta of 1.42, suggesting that its stock price is 42% more volatile than the S&P 500. Comparatively, Five Prime Therapeutics has a beta of 4.4, suggesting that its stock price is 340% more volatile than the S&P 500.

Profitability

This table compares Ionis Pharmaceuticals and Five Prime Therapeutics' net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Ionis Pharmaceuticals and Five Prime Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Ionis Pharmaceuticals has higher revenue and earnings than Five Prime Therapeutics. Five Prime Therapeutics is trading at a lower price-to-earnings ratio than Ionis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Ionis Pharmaceuticals beats Five Prime Therapeutics on 11 of the 14 factors compared between the two stocks.